Staar Surgical Company · NASDAQ:STAA
Staar Surgical — Investor Presentation (February 2022)
27 slides from Staar Surgical's investor presentation, Feb 1, 2022
Slide 1: STAAR Surgical Investor Presentation
STAAR Surgical Investor Presentation NASDAQ: STAA | February 2022
Slide 2: Forward Looking Statements
All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections (including sales), plans, strategies, and objectives of management for 2022 or prospects for achieving such plans, expectations for sal
Slide 3: Who Is STAAR Surgical?
Who Is STAAR Surgical? Proprietary Implantable Collamer® lens (ICL) technology for refractive vision correction Executing against a rapidly expanding global TAM of millions of eyes Primary positioning, collaborative business model and clinical validation are driving industry-leading growth Strong fi
Slide 4: What is Refractive Vision Correction?
What is Refractive Vision Correction? 04 Surgical procedures designed to correct refractive error (Blurred Vision*) We believe the future of refractive vision correction is lens-based… Refractive Error Myopia Presbyopia Lens-Based e.g., EVO ICL Laser-Cornea Based Astigmatism Refractive Surgery Types
Slide 5: Refractive Error is a Global Epidemic
Refractive Error is a Global Epidemic * Global prevalence of clinically significant astigmatism (>0.75D), Market Scope, 2019. ** BHVI, adapted from Holden et al. 2016 Ophthalmology. *** Fricke, Global Prevalence of Presbyopia and Vision Impairment from Uncorrected Presbyopia, 2018. 05 75-80% of ages
Slide 6: Myopia - The Existing Market is Millions of Eyes
Myopia - The Existing Market is Millions of Eyes * Market Scope estimates for 2021 published January 2022. One Eye = One Procedure. Procedures rounded to nearest 10,000. R.O.W = Rest of World. Industry reports estimate the global market for refractive procedures will grow from 4 million annually in
Slide 7: STAAR's TAM is Tens of Millions of Eyes
STAAR’s TAM is Tens of Millions of Eyes * Company estimates of viable market opportunity. Bilaterally, 35 Million Myopes = 70 Million Lenses and 55 Million Presbyopes = 110 Million Lenses. 07 Myopes Myopes Myopia Eyes Presbyopia Eyes Presbyopes Presbyopes Distance Vision (Nearsightedness) Target Mar
Slide 8: An Evolution in Visual Freedom: STAAR's ICL Technology
An Evolution in Visual Freedom 08 STAAR’S ICL TECHNOLOGY
Slide 9: ICLs are Designed to Correct Refractive Error
ICLs are Designed to Correct Refractive Error * The ICL is a “Phakic” lens that is implanted into the eye without removing the eye's natural crystalline lens. In cataract surgery or refractive lens exchange (RLE), “Aphakic” procedures, the natural crystalline lens of the patient is removed. 09 An IC
Slide 10: The ICL is Implanted in Front of the Natural Crystalline Lens
The ICL is Implanted in Front of the Natural Crystalline Lens 10 Natural Crystalline Lens ICL™ Iris
Slide 11: Happy ICL Patients
Happy ICL Patients * Packer, The Implantable Collamer Lens with a central port: review of the literature, Clinical Ophthalmology, 2018. 11 ICLs Implanted Globally 1M+ Would Elect STAAR’s EVO Implantable Collamer® Lens Again* 99.4% of Patients
Slide 12: Premium ICL Patient and Surgeon Advantages
Premium ICL Patient and Surgeon Advantages 12 Bio- Compatible Additive UV Protection Quality of Vision Eco- Friendly Collamer Material Upgradeable Removeable Quiet in the Eye Excellent Night Vision No Dry Eye Syndrome No Capital Equipment Investment
Slide 13: ICLs Around the World
“@} STAARSURGICAL 7 ra ICL es AROUND THE WORLD vider 9 0 Meo OG $e ae aa oN ae aH ify oN vyetlery, os ~ oo N Sole
Slide 14: China – Continuing Momentum in #1 Global Market
China – Continuing Momentum in #1 Global Market 14 Myopia widespread among Chinese population, and particularly teenagers* China: the first large market to adopt a model of strategic cooperation in 2016 “Hybrid” business model, which has 50+ STAAR employees on the ground in country working in concer
Slide 15: China – Continuing Momentum in #1 Global Market
* Company estimates of viable market opportunity. Bilaterally, 35 Million Myopes = 70 Million Lenses and 55 Million Presbyopes = 110 Million Lenses. 15 EVO ICL Clinic Video EVO ICL Promotional Event Sole leg Pan Patient Video China – Continuing Momentum in #1 Global Market Patient roadshows, in-pers
Slide 16: United States – Creating Success in #2 Global Market
United States – Creating Success in #2 Global Market * Company estimates of viable market opportunity. Bilaterally, 35 Million Myopes = 70 Million Lenses and 55 Million Presbyopes = 110 Million Lenses. 16 Strategic Imperative Drive U.S. growth, where STAAR currently has < 1% share with an earlier ge
Slide 17: Europe – Accelerating a Growth Renaissance
Europe – Accelerating a Growth Renaissance Driving growth via Surgeon Support, Strategic Sales & Marketing Investments Increasing commitment to ICL by surgeons: German refractive society expanded recommended range for use of phakic refractive lenses, including EVO from -6.0D to -3.0D* Increasing dis
Slide 18: We're Just Getting Started…
We’re Just Getting Started… * Approximate ICL unit share of 2021 global refractive myopia market. 18 ~ 9% ICL share of global market*
Slide 19: STAAR's Track Record of Strong Financial Performance
19 STAAR’s Track Record of Strong Financial Performance
Slide 20: ICL Unit Growth Significantly Exceeds Refractive Industry
ICL Unit Growth Significantly Exceeds Refractive Industry * Market Scope, January 2019-2022. 20
Slide 21: STAAR's Industry Leading Net Sales Growth ~ +25% CAGR
STAAR’s Industry Leading Net Sales Growth ~ +25% CAGR * Initial sales outlook provided prior to COVID on January 13, 2020, was for sales mid-point of $177 million or +18% Y/Y Growth for 2020. ** Fiscal 2021 and 4Q21P is preliminary as reported on January 10, 2022. CAGR of 26% for 2017-2021 and 24% f
Slide 22: STAAR's Expanding Margins, EPS and Cash
STAAR’s Expanding Margins, EPS and Cash * 2019 Includes $0.07 GILTI tax benefit. 2021 EPS is preliminary as reported January 10, 2022. ** 4Q21P is preliminary. Cash includes net proceeds of approximately $72 million from August 2018 secondary offering. 22 Operating Margin Cash on Balance Sheet - Qua
Slide 23: Impactful Consumer Marketing Driving ICL Awareness
Impactful Consumer Marketing has driven Increasing ICL Awareness, Doctor Finder Visits and Patients to Surgeons. STAAR intends to make significant incremental investments in awareness building activities in fiscal 2022… 23 Evolution in Visual Freedom TM STAAR Will Increase Investment in ICL Awarenes
Slide 24: Recent Highlights and Outlook
Recent Highlights and Outlook Reported preliminary sales results for fiscal 2021 on January 10, 2022 STAAR is committed to continuing to push hard to overcome Covid-related challenges Doubling the footprint at principal manufacturing facility through movement of non-production floor space requiremen
Slide 25: STAAR's Vision 2020-2022
Position EVO Implantable Lenses as a Special and Transformational Pathway to Visual Freedom… Promote Exceptional Desirability to Win Consumer Choice and Social Media Enthusiasm We have a Passionate Commitment to Deliver Visual Freedom to Patients for an Active and Fulfilling Life Independent of Cont
Slide 26: STAAR's ESG Commitment
STAAR’s ESG Commitment 26 Published second annual Sustainability Report in 2021 and elevated ESG stewardship to a strategic imperative Several projects completed or underway designed to reduce energy, waste and water, e.g., initial analysis of solar photovoltaic panel initiative indicates STAAR will
Slide 27: Visit STAAR's investor website
We invite you to visit STAAR’s investor website for clinical papers, examples of global consumer marketing and much more at investors.staar.com www.staar.com www.discoverevo.com
STAAR Surgical — Investor Presentation (February 2022) on 6ix